About BCI Pharma
BCI Pharma is a company based in Grabels (France) founded in 2013 was acquired by Gedeon Richter in June 2024. BCI Pharma has raised $4.7 million across 1 funding round from investors including Gedeon Richter and Wallonia. BCI Pharma offers products and services including Medicinal Chemistry Platform, Biology Platform, and Kinase Inhibitor Platform. BCI Pharma operates in a competitive market with competitors including Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and ICE Bioscience, among others.
- Headquarter Grabels, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.7 M (USD)
in 1 rounds
-
Latest Funding Round
$4.7 M (USD), Series A
Mar 12, 2018
-
Investors
Gedeon Richter
& 1 more
-
Employee Count
Not available
-
Acquired by
Gedeon Richter
(Jun 19, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BCI Pharma
BCI Pharma offers a comprehensive portfolio of products and services, including Medicinal Chemistry Platform, Biology Platform, and Kinase Inhibitor Platform.
Platform for discovering novel kinase inhibitors.
Tools for biological testing in drug discovery processes.
Technology to develop potent inhibitors for medical applications.
People of BCI Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of BCI Pharma
BCI Pharma has successfully raised a total of $4.7M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.7 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BCI Pharma
BCI Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gedeon Richter and Wallonia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access to government programs and development services is facilitated.
|
Locked | Locked | Locked | |
|
Generic and biosimilar drugs are manufactured by Gedeon Richter.
|
Locked | Locked | Locked |
Investor details for BCI Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BCI Pharma
Investment portfolio details for BCI Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BCI Pharma
Detailed financials for BCI Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bci Pharma Comparisons
Peer comparison for BCI Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BCI Pharma
BCI Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Reaction Biology, ImmunoSCAPE, PhenoVista, Discovery Biomed and ICE Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
High-dimensional immune profiling services are delivered via proprietary platform.
|
|
| Locked | Locked | Locked |
A CRO that provides phenotypic assay development and screening services.
|
|
| Locked | Locked | Locked |
Custom human cell engineering and drug discovery services are provided.
|
|
| Locked | Locked | Locked |
Specialised CRO offering a range of screening platforms for cardiac safety testing, ion channel profiling and in vitro HTS screening
|
Detailed competitors of BCI Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bci Pharma
Complete news archive for BCI Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BCI Pharma
BCI Pharma was founded in 2013 and raised its 1st funding round 5 years after it was founded.
BCI Pharma is headquartered in Grabels, France. It is registered at Grabels, Herault, France.
BCI Pharma is a funded company, having raised a total of $4.7M across 1 funding round to date.
BCI Pharma was founded in 2013 and is based in Grabels, France. Operations focus on the pharmaceutical sector as a contract research organization, with projects centered on cancer, neuropathic pain, inflammation, and neuroinflammation related to multiple sclerosis, Alzheimers, and ALS. Chemical libraries, including kinase and macrocyclic peptide types, are developed. Services encompass library synthesis, medicinal chemistry, and consultancy to support drug discovery processes.
BCI Pharma's top competitors include ImmunoSCAPE, Quantumcyte and Reaction Biology.
BCI Pharma offers Medicinal Chemistry Platform, Biology Platform, and Kinase Inhibitor Platform.
BCI Pharma has 2 investors. Key investors include Gedeon Richter, and Wallonia.